Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients

Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients - Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013539

Enrollment

Registered

2014-03-31

Start date

2014-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

SGLT-2 inhibitor(-) SGLT-2 inhibitor(+)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.HbA1c >=8.0 inadequately controlled type 2 diabetic patients 2. age >=20, <75 3.BMI >=22 kg/m2, and eGFR >=45 ml/min/1.73m2 4. patients who can get written consent

Exclusion criteria

Exclusion criteria: 1.age <20, >=75 2.BMI <22 kg/m2 3.eGFR <45 ml/min/1.73m2 4. anti-GAD antibody titer >=10 or insulin-dependent 5. patients who have anemia (Hb male <12 g/dl, female <11 g/dl) 6. patients who have cancer, or infection 7. patients judged to be disqualified to this research by physicians

Design outcomes

Primary

Measure	Time frame
Duration of insulin usage, Rate of insulin withdrawal, Change rate of body weight, Incidence rate of hypoglycemia	—

Secondary

Measure	Time frame
Diabetic duration, Body weight, HOMA-B,HOMA-R, delta C-peptide, Blood pressure, LDL-C, HDL-C, TG, UA, Ketone bodies in blood, FFA, Renin activity, Aldosterone, Glucose concentration in urine, Microalbumin in urine, Protein in urine, NAG in urine, Beta-2 microglobulin in urine, Ca excretion in urine, C-peptide in urine, Amino acids in urine	—

Countries

Japan

Contacts

Public ContactKen-ichi Nemoto

Shiga University of Medical Science, Department of Internal Medicine Devision of Endocrinology and Metabolism

knemoto@belle.shiga-med.ac.jp+81-77-548-2223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026